U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487727) titled 'A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)' on March 17.

Brief Summary: This is a pilot phase III, randomized, open-label, active-controlled study to evaluate the safety and efficacy of AND017 in NDD-CKD patients

Study Start Date: Dec. 03, 2025

Study Type: INTERVENTIONAL

Condition: Anemia Due to Chronic Kidney Disease

Intervention: DRUG: AND017

AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients

DRUG: ESA

ESA injection and dose based on package insert an...